Last updated on October 2020

Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

Brief description of study

Primary Objective:

To evaluate the efficacy of dupilumab in patients with persistent asthma

Secondary Objectives:

  • To evaluate the safety and tolerability of dupilumab
  • To evaluate the effect of dupilumab on improving patient reported outcomes including health related quality of life
  • To evaluate dupilumab systemic exposure and immunogenicity

Detailed Study Description

The total duration of study per patient is approximately 40 weeks, including 3 to 5 weeks of screening period, 24 weeks of treatment period and 12 weeks of post-treatment period.

Clinical Study Identifier: NCT03782532

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.